Luminal- and basal-like prostate cancers demonstrate divergent clinical behavior, and patients with luminal B tumors respond better to postoperative ADT than do patients with non–luminal B tumors. These findings contribute novel insight into prostate cancer biology, providing a potential clinical tool to personalize ADT treatment for prostate cancer by predicting which men may benefit from ADT after surgery.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: